Jazz Pharmaceuticals News and Activities

Presence

Jazz Pharmaceuticals develops and sells specialty medicines. Its main products treat sleep disorders, cancer, and rare diseases for hospitals, doctors, and patients in the United States and other markets.

Jazz Pharmaceuticals products and services overview:

Sleep medicine
Cancer therapies
Rare disease drugs
Neuroscience treatments
Emergency care drugs

Revenue: ~$4 billion

Employees: 2,800

Headquarters: Palo Alto, United States (USA)

Jazz Pharmaceuticals is one of the...

Jazz Pharmaceuticals is a company listed under the stock ticker JAZZ (US).

Jazz Pharmaceuticals has a direct presence in 3 countries.

Acquisition, funding and merger involving Jazz Pharmaceuticals.

Jazz Pharmaceuticals has acquired Chimerix (posted on March 6 2025).

Executives

View the org chart displaying its 48 main executives

Most searched biographies at Jazz Pharmaceuticals

Popular executive movements at Jazz Pharmaceuticals

Anne O'Riordan, Director, has left the company (posted on June 1 2026).
Sonia Hardaway, who was Head of Organizational and Talent Solutions, is promoted to Vice President, People & Culture (posted on April 2 2026).
Thomas Riga has joined the company as Chief Business Officer (posted on January 9 2026).

Click here to view some more movements at Jazz Pharmaceuticals

Create your alert
to follow the executive moves at Jazz Pharmaceuticals.